MoneyWorks4Me

Emmessar Biotech&Nut - Quaterly Results

04 Feb 2023 Evaluate
The total revenue hovered 166.87% to Rs. 4.27 millions for the December 2022 quarter as against Rs. 1.60 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2022 is Rs. -0.23 millions as compared to Net Profit of Rs. 1.69 millions of corresponding quarter ended December 2021Operating profit for the quarter ended December 2022 rose to 2.73 millions as compared to 1.92 millions of corresponding quarter ended December 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 4.27 1.60 166.87 7.03 2.19 221.00 3.65 69.91 -94.78
Other Income 4.45 4.08 9.07 13.18 12.13 8.66 19.19 14.66 30.90
PBIDT 2.73 1.92 42.19 7.89 4.95 59.39 10.25 23.12 -55.67
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT 2.73 1.92 42.19 7.89 4.95 59.39 10.25 23.12 -55.67
Depreciation 0.24 0.23 4.35 0.70 0.55 27.27 0.92 0.58 58.62
PBT 2.49 1.69 47.34 7.19 4.40 63.41 9.33 22.54 -58.61
TAX 2.72 0.00 0.00 4.12 0.00 0.00 4.57 8.05 -43.23
Deferred Tax 1.72 0.00 0.00 2.12 0.00 0.00 0.22 4.48 -95.09
PAT -0.23 1.69 -113.61 3.07 4.40 -30.23 4.76 14.49 -67.15
Equity 49.96 49.96 0.00 49.96 49.96 0.00 49.96 49.96 0.00
PBIDTM(%) 63.93 120.00 -46.72 112.23 226.03 -50.35 280.82 33.07 749.15
Peers
Company Name CMP
Sun Pharma. Inds. 1842.00
Dr. Reddys Labs. 1161.00
Cipla 1365.00
Lupin 2096.00
Zydus Lifesciences 1119.50
View more..